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ed April 7, 2013.his study sought to evaluate the relationship between glycemic control and cardiovascular disease (CVD)
hospitalizations and all-cause mortality among patients with type 2 diabetes in a real-world setting.Background Clinical trials have not established that tight glycemic control reduces CVD events and may be associated with
increased mortality. Observational studies of speciﬁc cohorts have reported increased risk of those outcomes at
both high and low glycosylated hemoglobin (HbA1c) levels.Methods Using the mean of all HbA1c measures over a mean follow-up of 6 years, we created categories of HbA1c (<6.0%,
6.0% to 6.4%, 6.5% to 6.9%, 7.0% to 7.4%, 7.5% to 7.9%, 8.0% to 8.4%, 8.5% to 8.9%, and 9.0%) to estimate the
risk of CVD hospitalization and all-cause mortality associated with glycemic control, adjusting for demographic and
clinical characteristics among 26,673 members of Kaiser Permanente Northwest with type 2 diabetes.Results Compared with patients with mean HbA1c levels 7.0% to 7.4%, those with mean HbA1c levels <6.0% had
a 68% increased risk of CVD hospitalization (hazard ratio [HR]: 1.68 [95% conﬁdence interval (CI): 1.39 to 2.04],
p < 0.001) after adjustment for demographic and clinical characteristics. Those with HbA1c levels 6.0% to 6.4% (HR:
1.18 [95% CI: 1.00 to 1.40], p ¼ 0.048) and 6.5% to 6.9% (HR: 1.18 [95% CI: 1.02 to 1.37], p ¼ 0.031) also had
signiﬁcantly higher risk relative to the reference group of 7.0% to 7.4%, as did patients with HbA1c levels 8.5% to
8.9% (HR: 1.55 [95% CI: 1.24 to 1.94], p < 0.001) and 9.0% (HR: 1.83 [95% CI: 1.50 to 2.22], p < 0.001). Risk of
all-cause mortality was signiﬁcantly greater than the reference group among HbA1c categories <6.0%, 6.0% to
6.4%, 6.5% to 6.9%, and 9.0%.Conclusions The relationship between mean HbA1c and CVD hospitalizations and all-cause mortality was U-shaped, with greater
risk at both higher and lower HbA1c levels. (J Am Coll Cardiol 2013;62:121–7) ª 2013 by the American College of
Cardiology FoundationThe American Diabetes Association has long recommended
that patients with type 2 diabetes strive for glycosylated
hemoglobin (HbA1c) levels <7.0%. Historically, this
recommendation was based on the ﬁndings of the UKPDS
(United Kingdom Prospective Diabetes Study) (1), which
showed that intensive therapy that achieved median HbA1c
levels of 7.0%, compared with 7.9% in the conventional
therapy group, reduced the rate of microvascular complica-
tions by 25% (2). Although reduction of cardiovascular
disease (CVD) did not reach statistical signiﬁcance (p ¼
0.052), subsequent epidemiological evidence revealed that ther for Health Research, Portland, Oregon; and
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, 2012; revised manuscript received March 26,association between HbA1c and CVD was continuous, with
no threshold below which further risk reduction was not
achieved (3), thus solidifying the HbA1c recommendation.
The glycemic goal of HbA1c levels<7.0% remained largely
unquestioned until the ACCORD (Action to Control
Cardiovascular Risk in Diabetes), ADVANCE (Action in
Diabetes and Vascular Disease: Preterax and Diamicron
Modiﬁed-Release Controlled Evaluation), and VADT
(Veterans Affairs Diabetes Trial) studies were unable to
establish that tight glycemic control (HbA1c targets 6.5%)
reduced CVD events, and the ACCORD study showed an
associationwith increasedmortality (4–6). Subsequent studies
conducted among observational cohorts that intensiﬁed
therapy (7), in the elderly (8,9), and in veterans with heart
failure (10) reported an increased risk of mortality and CVD
events at both high and low HbA1c levels. Therefore, the
objectives of the current studywere to evaluate the relationship
between glycemic control and CVD hospitalizations and
all-cause mortality among a more general diabetes population
in a real-world clinical setting followed up for up to 10 years.
Abbreviations
and Acronyms
CI = conﬁdence interval
CVD = cardiovascular
disease
HbA1c = glycosylated
hemoglobin
HR = hazard ratio
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122Methods
Sample selection. This was a
retrospective observational cohort
study conducted by using the ele-
ctronic medical records of patients
with type 2 diabetes enrolled by
Kaiser Permanente Northwest, an
integrated healthcare delivery sys-
tem that provides comprehensivemedical services to approximately 480,000 individuals in
a 75-mile radius around Portland, Oregon. We identiﬁed
26,673 individuals age 18 years who were diagnosed with
diabetes from 1997 to 2007, had a health plan enrollment
period between 2002 and 2011, and did not receive insulin
within the ﬁrst year of diabetes diagnosis. All patients were
required to have HbA1c, systolic blood pressure, and low-
density lipoprotein cholesterol measured after diabetes diag-
nosis but no more than 6 months apart between 2002 and
2008. The date of the HbA1c test during the ﬁrst occurrence
of the 3-test combination became the index date. Thus, the
index date was not equivalent to the diagnosis date. We
excluded patients with a CVD hospitalization before the
index date.
Outcomes and observation periods. We examined 2
outcomes independently and as a composite. The ﬁrst
outcome was a ﬁrst observed hospitalization with a primary
diagnosis of CVD (International Classiﬁcation of Diseases-
Ninth Revision-Clinical Modiﬁcation, codes 410.x, 411.x,
413.x, 414.x) or stroke (codes 430.x, 431.x, 432.x, 434.x,
435.x, 436.x, 437.1). The observation period was from the
index date until patients ﬁrst experienced the outcome, with
censoring if they died or left the health plan, or on
December 31, 2011. The second outcome was all-cause
mortality, with an observation period from the index date
until death, with censoring if they left the health plan or on
December 31, 2011. The observation period for the
composite outcome was from the index date until the earliest
occurrence of death or a CVD hospitalization, with
censoring if the patient left the health plan or on December
31, 2011.
Exposure variable. The exposure variable was the mean of
all HbA1c measures during the observation periods. Based
on mean values, we used 0.5% increments of HbA1c to
categorize patients into 8 levels of glycemic control: <6.0%,
6.0% to 6.4%, 6.5% to 6.9%, 7.0% to 7.4%, 7.5% to 7.9%,
8.0% to 8.4%, 8.5% to 8.9%, and 9.0%. Because the
observation periods for the 2 outcomes were of different
length, patients could be in a different category for each
outcome, but 87% were in the same category for all analyses.
Statistical analyses. We calculated incidence rates for CVD
hospitalizations and all-cause mortality per 1,000 person-
years for each HbA1c category by using generalized linear
regression with Poisson errors and the natural log of person-
years as an adjustment for unequal follow-up. PROC
GENMOD in SAS version 9.2 (SAS Institute, Cary, NorthCarolina) was used, controlling for baseline age, sex, and
duration of diabetes. A Cox proportional hazards regression
analysis was used to more fully adjust the comparisons of
HbA1c categories and to evaluate the continuous relationship
between HbA1c and the outcomes. The models adjusted
for age, sex, diabetes duration, African-American race,
smoking status, other clinical CVD risk factors (systolic blood
pressure, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, and body mass index)
recorded in the outpatient setting within 6 months before
or after the index date. We also included variables for
presence of macrovascular complications (a composite of
ischemic heart disease, stroke, and heart failure) and presence
of microvascular complications (retinopathy, neuropathy, or
chronic kidney disease deﬁned by a glomerular ﬁltration
rate <60 ml/min/1.73 m2) recorded in the outpatient setting
any time before the index date. We also adjusted for use
of antihypertensive medications (angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, diuretics,
beta-blockers), oral antihyperglycemic agents (metformin,
sulphonylureas, thiazolidinediones, alpha-glucosidase inhib-
itors, meglitinides, and dipeptidyl peptidase-4 inhibitors),
insulin, and statins within 90 days of the index date. To
account for the possibility that HbA1c testing was related to
the outcomes, we controlled for the number of tests per year
of follow-up. We tested the proportional hazards assumption
by creating interaction terms between survival time and the
HbA1c categories; none of the interaction terms was signiﬁ-
cant, indicating each was proportional. The proportionality
test of all time-dependent covariates at once produced a
p value of 0.10, indicating the proportionality assumption
was met.
Results
Patient characteristics for each category of mean HbA1c
analyzed for the composite outcome are displayed in
Table 1. Patients in lower HbA1c categories were older, with
slightly shorter diabetes duration compared with patients in
higher HbA1c categories. Those in lower HbA1c categories
were more likely to have macrovascular complications and
less likely to be using insulin. Nearly identical results were
observed when examining patient characteristics across
HbA1c categories analyzed for CVD hospitalizations or all-
cause mortality (data not shown to avoid redundancy).
Variability of HbA1c values among patients in each
HbA1c category is shown in Table 2. SDs and coefﬁcients of
variation were low in all HbA1c categories. The proportion
of all HbA1c measurements that occurred within the cate-
gory range was greater among lower HbA1c categories except
for HbA1c 9.0%, as was the mean difference between each
individual HbA1c measurement and the patients’ mean
values. The number of tests per year of observation was
consistent across categories.
Incidence rates. Among the 26,673 study subjects, 2,176
(8.2%) experienced a CVD hospitalization, 3,360 (12.6%)
Table 1 Characteristics of Study Cohort by Mean HbA1c During Follow-Up Using Composite of CVD Hospitalization and All-Cause Mortality as the Outcome
Characteristic
Mean HbA1c During Follow-Up
Total<6.0% 6.0%–6.4% 6.5%–6.9% 7.0%–7.4% 7.5%–7.9% 8.0%–8.4% 8.5%–8.9% 9.0%
Age (yrs) 61.8  13.2 62.8  12.0 61.7  11.5 60.2  11.3 57.8  11.3 55.9  10.8 53.9  10.6 50.5  10.6 59.1  12.1
Length of follow-up (yrs) 5.3  2.7 5.6  2.7 6.1  2.6 6.4  2.6 6.5  2.6 6.4 2.6 6.2  2.7 5.7 2.7 6.0  2.7
Male 51.4 49.1 46.7 50.3 50.5 53.3 53.3 52.7 50.2
African-American 2.3 2.1 3.1 2.8 2.8 4.3 5.0 5.0 3.2
Smoker 12.9 11.3 11.1 12.2 14.5 15.0 14.6 18.7 13.2
Duration of diabetes (yrs) 2.5  3.6 2.5  3.6 3.1  4.1 3.8  4.5 4.2  4.7 4.4 4.8 4.2  4.7 4.0 4.4 3.5  4.3
Body mass index (kg/m2) 34  8 34  8 34  7 34  7 35  7 35 8 36  7 35  8 34  8
GFR (ml/min/1.73 m2) 85  35 85  27 88  29 89  27 93  30 97 31 100  30 106  33 91  30
SBP (mm Hg) 135  19 136  19 136  18 136  19 136  18 137 19 136  19 134  19 136  19
LDL cholesterol (mg/dl) 108  33 109  34 110  33 110  34 111  33 112  34 113  35 118  37 111  34
HDL cholesterol (mg/dl) 49  13 48  11 48  11 47  11 47  11 47  11 46  10 46  10 47  11
Triglycerides (mg/dl) 203  219 207  178 214  191 222  196 233  231 244  245 252  262 258  268 225  216
Macrovascular complications 23.6 22.1 20.1 18.9 17.0 16.1 13.0 12.0 18.6
Microvascular complications 26.8 25.8 25.3 26.4 26.5 26.7 24.0 23.1 25.7
Antihypertensive agents 61.7 64.7 63.2 59.0 57.3 54.7 51.3 42.6 58.4
Oral antihyperglycemics 34.9 38.4 45.9 53.6 59.9 62.9 63.0 65.5 51.3
Insulin 3.9 3.7 6.6 9.8 12.0 14.0 14.6 13.3 8.9
Statin 29.9 37.2 35.8 34.0 33.5 30.7 28.4 23.6 32.9
Values are mean  SD or %.
CVD ¼ cardiovascular disease; GFR ¼ glomerular ﬁltration rate; HDL ¼ high-density lipoprotein cholesterol; HbA1c ¼ glycosylated hemoglobin; LDL ¼ low-density lipoprotein cholesterol; SPB ¼ systolic blood pressure.
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124died, and 4,853 (18.2%) experienced either outcome
(Table 3). The proportion of patients with a CVD hospi-
talization according to HbA1c category ranged from 7.3% to
9.3%. All-cause mortality seemed to be inversely related to
HbA1c category, ranging from 20.4% to 7.4%. CVD
hospitalization incidence was greatest among patients with
mean HbA1c levels 9.0% (18.2 per 1,000 person-years
[95% conﬁdence interval (CI): 15.9 to 21.0]), followed by
those with HbA1c levels 8.5% to 8.9% (14.6 per 1,000
person-years [95% CI: 12.3 to 17.4]) and <6.0% (13.4 per
1,000 person-years [95% CI: 11.6 to 15.3]). Incidence rates
for all other categories were signiﬁcantly lower and statisti-
cally similar to one another. Mortality was highest among
those with mean HbA1c levels <6.0% (17.5 per 1,000
person-years [95% CI: 15.8 to 19.4]) and was also statisti-
cally higher among those with mean HbA1c levels 6.0% to
6.4% (13.1 per 1,000 person-years [95% CI: 12.0 to 14.3])
and 9.0% (15.3 per 1,000 person-years [95% CI: 13.2 to
17.7]) compared with other HbA1c categories. Adjusted
incidence rates for the composite outcome were also statis-
tically signiﬁcantly greater among the two highest and two
lowest HbA1c categories.
Hazard ratios. Results of adjustment using Cox regression
models and the covariates displayed in Table 1 are portrayed
in Figure 1. Compared with patients with mean HbA1c levels
7.0% to 7.4%, those with mean HbA1c levels <6.0% had
a 68% increased risk of CVD hospitalization (hazard ratio
[HR]: 1.68 [95% CI: 1.39 to 2.04], p< 0.001). Risk was also
statistically higher among those in HbA1c categories 6.0% to
6.4% (HR: 1.18 [95% CI: 1.00 to 1.40], p¼ 0.048) and 6.5%
to 6.9% (HR: 1.18 [95% CI: 1.02 to 1.37], p ¼ 0.031).
Patients with HbA1c levels 8.5% to 8.9% (HR: 1.58 [95%CI:
1.26 to 1.99], p < 0.001) and 9.0% (HR: 1.98 [95% CI:
1.62 to 2.41], p< 0.001) also had signiﬁcantly greater risk of
CVD hospitalization relative to the reference group. Risk of
all-cause mortality was signiﬁcantly greater than the reference
group among the HbA1c categories <6.0%, 6.0% to 6.4%,
6.5% to 6.9%, and9.0%. Results for the composite outcome
showed greater risk among patients with HbA1c in
categories <7.0% and 8.5%. The full Cox models are dis-
played in Online Table 1.
Discussion
In a general cohort of 26,673 diabetes patients followed up
for a mean of 6.0 years, the relationship between mean
HbA1c and CVD hospitalizations and all-cause mortality
was approximately U-shaped. Age-, sex-, and duration-
adjusted incidence of CVD hospitalizations and mortality
was greatest among patients with relatively high mean
HbA1c levels (8.5%) and also among those with low mean
HbA1c levels (<7.0%). These results were robust after
further adjustment for known CVD risk factors, complica-
tions, and medications typical of patients with diabetes.
Ours is not the ﬁrst study to observe an association
between both high and low HbA1c levels and increased risk
Table 3 Number of Subjects, Proportion With Each Outcome, and Incidence of Outcomes per 1,000 Person-Years Adjusted for Age, Sex, and Duration of Diabetes, by HbA1c Category
Outcome
Mean HbA1c During Follow-Up
Total<6.0% 6.0%–6.4% 6.5%–6.9% 7.0%–7.4% 7.5%–7.9% 8.0%–8.4% 8.5%–8.9% 9.0%
CVD hospitalization
n in category 2,348 4,253 5,345 4,912 3,550 2,318 1,449 2,498 26,673
n (%) with outcome 219 (9.3%) 332 (7.8%) 444 (8.3%) 395 (8.0%) 280 (7.9%) 170 (7.3%) 128 (8.8%) 208 (8.3%) 2,176 (8.2%)
Adjusted incidence/
1,000 person-years (95% CI)
13.4 (11.6–15.3) 10.2 (9.1–11.5) 10.4 (9.4–11.5) 9.7 (8.8–10.8) 10.3 (9.1–11.6) 10.5 (9.0–12.2) 14.6 (12.3–17.4) 18.2 (15.9–21.0) 11.5 (10.1–13.0)
All-cause mortality
n in category 2,302 4,214 5,352 4,960 3,595 2,354 1,440 2,456 26,673
n (%) with outcome 470 (20.4%) 681 (16.2%) 715 (13.4%) 603 (12.2%) 355 (10.6%) 236 (10.0%) 118 (8.2%) 182 (7.4%) 3,360 (12.6%)
Adjusted incidence/
1,000 person-years (95% CI)
17.5 (15.8–19.4) 13.1 (12.0–14.3) 10.5 (9.6–11.4) 9.7 (8.8–10.6) 9.0 (8.1–10.1) 10.9 (9.5–12.4) 11.3 (9.4–13.5) 15.3 (13.2–17.7) 11.7 (10.5–12.9)
Composite outcome
n in category 2,348 4,253 5,345 4,912 3,550 2,318 1,449 2,498 26,673
n (%) with outcome 609 (25.9%) 898 (21.1%) 997 (18.7%) 878 (17.9%) 552 (15.6%) 350 (15.1%) 214 (14.8%) 355 (14.2%) 4,853 (18.2%)
Adjusted incidence/
1,000 person-years (95% CI)
30.1 (27.6–32.8) 22.6 (21.0–24.3) 19.4 (18.1–20.7) 18.4 (17.1–19.7) 17.8 (16.3–19.4) 19.7 (17.7–22.0) 23.5 (20.4–26.9) 31.9 (28.8–35.4) 21.9 (20.1–23.8)
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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126of CVD events or mortality. Aguilar et al. (10) reported that
in U.S. veteran patients with diabetes and heart failure, the
lowest risk of mortality occurred among those with baseline
HbA1c levels 7.1% to 7.8%. An analysis of the UK General
Practice Research Database found a U-shaped relationship
between mean HbA1c levels and mortality and large-vessel
disease over 4.5 years after diabetes treatment escalation
(7). Two other studies conducted among elderly subjects
reported increased risk of CVD or mortality at high and
low HbA1c levels (8,9). The current study conﬁrms the
U-shaped relationship between HbA1c and CVD hospital-
izations and mortality in a general population suggested by
these more speciﬁc cohort studies.
An observational analysis of UKPDS data found that
each 1% reduction of updated mean HbA1c level was
associated with 14% reductions in risk of all-cause mortality
and myocardial infarction (3). The UKPDS was a trial of
newly diagnosed type 2 diabetes participants in whom
vascular damage from long-term exposure to hyperglycemia
may not yet have occurred. Indeed, studies of patients
without diabetes have shown a continuous relationship
between HbA1c levels and CVD and mortality (11–13),
although the Strong Heart Study found no such relation-
ship (14). It may be that established diabetes patients with
more cumulative exposure to hyperglycemia exhibit a dif-
ferent relationship between HbA1c levels and CVD and
mortality than nondiabetic or newly diagnosed patients.
However, at least 1 cohort study of general diabetes patients
in the Swedish National Diabetes Register found progres-
sive risk of CVD and mortality at higher but not lower
HbA1c levels, even among registrants with longer duration
of disease (15). Other studies suggest a threshold effect
such that risk of CVD events and mortality is increased at
higher levels of HbA1c but neither increased nor decreased
below 7.0% (16,17). Although the observational design
precludes the establishment of a causal relationship, our
data support the concept of a “sweet spot” for controlling
glycemia in type 2 diabetes (18) and also support the recent
position statement from the American Diabetes Associa-
tion and the European Association for the Study of Dia-
betes that argues for a patient-centered approach to
glycemic control (19).
We observed some potentially important differences in
the characteristics of patients with low versus high mean
HbA1c levels. Speciﬁcally, mean age among those with low
HbA1c levels (<6.0% and 6.0% to 6.5%) was approximately
62 years, with a mean duration of diabetes of about 2 years.
Mean age at diagnosis was therefore about 60 years. In
contrast, patients with high mean HbA1c levels (8.5% to
8.9% and 9.0%) had a mean age at diagnosis of <50 years.
Mean body mass index and systolic blood pressure were
somewhat lower among those patients with low versus high
HbA1c levels. Taken together, these data suggest that we
may be observing different “phenotypes” of type 2 diabetes,
with differential contribution of insulin resistance and beta
cell failure. If so, how glycemia is lowered may be asimportant as how much it is lowered. Further exploration of
this hypothesis is warranted but is beyond the scope of the
current study.
Study limitations. First, as an observational study, we
cannot conclude that the observed associations were causal.
It is possible that unmeasured confounders contributed to
our results. It is also possible that multiple underlying
mechanisms are at work, the sum total of which contributes
to the associations we report. Thus, our results must be
viewed with caution. Second, we did not attempt to adju-
dicate CVD hospitalization events, relying on the accuracy
of coding of inpatient diagnoses. Third, we used statistical
models to account for heterogeneity between HbA1c cate-
gories, but confounding from unmeasured variables may
remain. However, the associations between HbA1c and age,
sex, and duration-adjusted incidence rates of the outcomes
were robust when we further adjusted for clinical charac-
teristics. The sequential addition of blocks of variables had
little to no effect on the size or signiﬁcance of the HRs for
the HbA1c categories. Fourth, we recognize that using the
mean of HbA1c values collected during follow-up violates
statistical assumptions of survival models. However, re-
analysis using time-dependent HbA1c measures did not
affect our ﬁndings and are more difﬁcult to interpret.
Therefore, we report our results in the most easily under-
stood manner possible. Last, the study beneﬁted from the
comprehensiveness of the electronic medical records
maintained by a fully integrated health system in which
patients are all insured and predominantly white; the results
may not generalize to other health systems with less
information technology support, a more diverse population,
or the uninsured.
Conclusions
In this large cohort of patients with type 2 diabetes, we
found an increased risk of CVD hospitalizations and all-
cause mortality at both higher and lower mean HbA1c
levels. Our results conﬁrm that maintaining HbA1c
levels <8.0% is important for the prevention of CVD events
and death. Lower HbA1c levels are recommended because of
well-established microvascular risk reduction (20). Without
accounting for how HbA1c is lowered, our results do not
support an HbA1c target level of <7.0% for CVD and
mortality prevention, a ﬁnding consistent with the
ACCORD trial and with other epidemiological analyses
(4,7–10). The current study supports a patient-centered
approach to managing hyperglycemia as recently advocated
by the American Diabetes Association and the European
Association for the Study of Diabetes that allows less-
stringent HbA1c targets for speciﬁc patients (19).
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APPENDIX
For a supplementary table on the study protocol, please see the online
version of this article.
